Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.85 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.75 |
| ▸ | DRD4 | P21917 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | FPR3 | P25089 | 1/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.75 |
| ▸ | HTR1D | P28221 | 1/20 | 0.75 |
| ▸ | HTR1B | P28222 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | GPR183 | P32249 | 1/20 | 0.75 |
| ▸ | HTR7 | P34969 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925758 | 0.92 | ADRB2 (1.00) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL4449305 | 0.90 | ADRB2 (0.72) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL4448758 | 0.90 | ADRB2 (0.92) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL28044430 | 0.88 | ADRB2 (0.85) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL9763066 | 0.88 | ADRB2 (0.74) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| Acetic Acid SCHEMBL927106 | 0.88 | ADRB2 (1.00) | ADRB2ADRB3ADRB1 | |
| SCHEMBL9763403 | 0.87 | ADRB2 (0.70) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL9763289 | 0.86 | ADRB2 (0.75) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL9763332 | 0.86 | ADRB2 (0.75) | ADRB2ADRB3ADRB1KDM4EHTR1A | |
| SCHEMBL926298 | 0.86 | ADRB2 (1.00) | ADRB2ADRB3ADRB1KDM4EHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285900-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2009-11-19 | — | — | US | disclosed |
| EP-1651168-A4 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1651168-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Epigenesis Pharmaceuticals LLC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050113318-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACUETICALS, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2005011603-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050026884-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113318-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | HSD3B2, ADRB2, HSD11B2 | ADRB2 2/4885ADRB3 14/4885ADRB1 13/4885 |
| US-20050026884-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | HSD3B2, HSD3B1, ADRB2 | ADRB2 3/4885ADRB3 14/4885ADRB1 10/4885 |
| US-20090285900-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD3B2, ADRB2, HSD11B2 | ADRB2 2/4885ADRB3 14/4885ADRB1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.